Kristian Stengaard-Pedersen

Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • S Møller-Bisgaard, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Department of Rheumatology, Slagelse Hospital, Slagelse
  • ,
  • B J Ejbjerg, Department of Rheumatology, Slagelse Hospital, Slagelse
  • ,
  • I Eshed, Department of Radiology, Sheba Medical Centre, Tel Hashomer
  • ,
  • K Hørslev-Petersen, King Christian X’s Hospital for Rheumatic Diseases, Graasten
  • ,
  • M L Hetland, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, The DANBIO Registry, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup
  • ,
  • A G Jurik
  • H Thomsen, Department of Radiology, Herlev-Gentofte University Hospital, Herlev,
  • T Torfing, Department of Radiology, Odense University Hospital, Odense, Denmark.
  • ,
  • K Stengaard-Pedersen
  • P Junker, Department of Rheumatology, Odense University Hospital, Odense, Denmark.
  • ,
  • N S Krogh, ZiteLab ApS, Copenhagen, Denmark.
  • ,
  • T Lottenburger, Department of Rheumatology, Vejle Hospital, Vejle
  • ,
  • T Ellingsen, Department of Rheumatology, Odense University Hospital, Odense, Denmark.
  • ,
  • L S Andersen, Department of Rheumatology, Gentofte and Herlev University Hospital, Gentofte, Denmark.
  • ,
  • H Skjødt, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup
  • ,
  • A J Svendsen, Department of Epidemiology, Institute of Public Health, University of Southern Denmark, Odense C, Denmark.
  • ,
  • U Tarp
  • ,
  • I T Hansen
  • J Pødenphant, Department of Rheumatology, Gentofte and Herlev University Hospital, Gentofte, Denmark.
  • ,
  • J K Pedersen, Department of Rheumatology, Odense University Hospital, Odense, Denmark.
  • ,
  • H Lindegaard, Department of Rheumatology, Odense University Hospital, Odense, Denmark.
  • ,
  • L G Hanson, Centre for Functional and Diagnostic Imaging and Research, Danish Research Centre for Magnetic Resonance (DRCMR), Copenhagen University Hospital Hvidovre, Hvidovre, Biomedical Engineering, DTU Elektro, Technical University of Denmark, Kongens Lyngby, Denmark.
  • ,
  • A Vestergaard, Department of Radiology, Copenhagen University Hospita Hvidovrel, Hvidovre
  • ,
  • M Glinatsi, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup
  • ,
  • M Østergaard, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup

OBJECTIVES: To investigate whether a treat-to-target strategy based on methotrexate (MTX) and intra-articular (IA) betamethasone suppresses magnetic resonance imaging (MRI)-determined measures of disease activity and reduces joint destruction in early rheumatoid arthritis (eRA) patients, and to investigate whether concomitant cyclosporin A (CyA) provides an additional effect.

METHOD: In the 2-year randomized, double-blind, treat-to-target trial CIMESTRA, 160 patients with eRA (< 6 months) were randomized to MTX, intra-articular betamethasone and CyA, or placebo CyA. A total of 129 patients participated in the MRI substudy, and had contrast-enhanced MR images of the non-dominant hand at months 0, 6, 12, and 24. MR images were evaluated for osteitis, synovitis, tenosynovitis, bone erosion, and joint space narrowing (JSN), using validated scoring methods.

RESULTS: Significant reductions were seen at 6 months in all inflammatory parameters [synovitis, mean change -1.6 (p < 0.001, Wilcoxon), tenosynovitis, -3.5 (p < 0.001), and osteitis, -1.3 (p < 0.05)] and at 12/24 months in synovitis and tenosynovitis [-1.6/-2.2 and -3.6/-3.8, respectively; all p < 0.001]. MRI signs of inflammation were not fully eliminated, and increases in erosion and JSN scores were observed at 6 months [0.4 (p < 0.01)/0.1 (p < 0.05)], 12 months [0.8 (p < 0.001)/0.3 (p < 0.01)], and 24 months [1.0 (p < 0.001)/0.4 (p < 0.001)]. Clinical measures decreased significantly (p < 0.001) at all time points. There were no consistent statistically significant differences between treatment groups.

CONCLUSIONS: In this eRA treat-to-target trial, MTX and intra-articular glucocorticoids markedly reduced, but did not eliminate, MRI osteitis, synovitis, and tenosynovitis. Accordingly, minimal but statistically significant increases in bone erosion and JSN were observed. No additional effect of CyA was demonstrated.

Original languageEnglish
JournalScandinavian Journal of Rheumatology
Volume46
Issue5
Pages (from-to)335-345
Number of pages11
ISSN0300-9742
DOIs
Publication statusPublished - 2017

See relations at Aarhus University Citationformats

ID: 107203085